Ensysce Biosciences, Inc. (ENSC) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Ensysce Biosciences, Inc. (ENSC) Bundle
Simplify Ensysce Biosciences, Inc. (ENSC) valuation with this customizable DCF Calculator! Featuring real Ensysce Biosciences, Inc. (ENSC) financials and adjustable forecast inputs, you can test scenarios and uncover Ensysce Biosciences, Inc. (ENSC) fair value in minutes.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.8 | 3.9 | 3.5 | 2.5 | 2.2 | 2.5 | 2.8 | 3.2 | 3.6 | 4.0 |
| Revenue Growth, % | 0 | 122.86 | -10.18 | -28.54 | -11.61 | 12.42 | 12.42 | 12.42 | 12.42 | 12.42 |
| EBITDA | .9 | -1.6 | -19.9 | -24.2 | -10.7 | -1.4 | -1.6 | -1.8 | -2.1 | -2.3 |
| EBITDA, % | 52.22 | -41.03 | -562.71 | -959.91 | -480.52 | -57.76 | -57.76 | -57.76 | -57.76 | -57.76 |
| Depreciation | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 0.01139481 | 0.00511293 | 0.00427617 | 0.00598403 | 0 | 0.00535359 | 0.00535359 | 0.00535359 | 0.00535359 | 0.00535359 |
| EBIT | .9 | -1.6 | -19.9 | -24.2 | -10.7 | -1.4 | -1.6 | -1.8 | -2.1 | -2.3 |
| EBIT, % | 52.21 | -41.04 | -562.71 | -959.91 | -480.52 | -57.77 | -57.77 | -57.77 | -57.77 | -57.77 |
| Total Cash | 1.1 | .2 | 12.3 | 3.1 | 1.1 | 1.6 | 1.8 | 2.0 | 2.2 | 2.5 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .4 | .3 | .1 | .1 | .2 | .2 | .2 | .2 |
| Account Receivables, % | 0 | 0 | 12.51 | 10.97 | 4.37 | 5.57 | 5.57 | 5.57 | 5.57 | 5.57 |
| Inventories | .0 | .0 | -.4 | -.3 | .0 | -.1 | -.1 | -.1 | -.2 | -.2 |
| Inventories, % | 0.000056690596 | 0 | -12.51 | -10.97 | 0 | -4.7 | -4.7 | -4.7 | -4.7 | -4.7 |
| Accounts Payable | .5 | 1.7 | .3 | 2.9 | 1.9 | 1.4 | 1.5 | 1.7 | 1.9 | 2.2 |
| Accounts Payable, % | 30.66 | 43.87 | 8.53 | 116.66 | 86.8 | 53.97 | 53.97 | 53.97 | 53.97 | 53.97 |
| Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 0 | 0 | 0 | 0 | 0.00008966519 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0.12423 | 0.12423 | 0.12423 | 0.12423 | 0.12423 | 0.12423 | 0.12423 | 0.12423 | 0.12423 | 0.12423 |
| EBITAT | 1.5 | -9.4 | -19.9 | -25.0 | -10.7 | -1.4 | -1.6 | -1.8 | -2.1 | -2.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 2.0 | -8.2 | -21.3 | -22.3 | -11.8 | -2.0 | -1.5 | -1.6 | -1.8 | -2.1 |
| WACC, % | 8.85 | 8.85 | 8.85 | 8.85 | 8.85 | 8.85 | 8.85 | 8.85 | 8.85 | 8.85 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -7.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -2 | |||||||||
| Terminal Value | -31 | |||||||||
| Present Terminal Value | -20 | |||||||||
| Enterprise Value | -27 | |||||||||
| Net Debt | 0 | |||||||||
| Equity Value | -27 | |||||||||
| Diluted Shares Outstanding, MM | 2 | |||||||||
| Equity Value Per Share | -11.91 |
What You Will Get
- Pre-Filled Financial Model: Ensysce Biosciences, Inc.’s (ENSC) actual data enables precise DCF valuation.
- Full Forecast Control: Adjust revenue growth, margins, WACC, and other key drivers specific to Ensysce.
- Instant Calculations: Automatic updates ensure you see results as you make changes to your forecasts.
- Investor-Ready Template: A refined Excel file designed for professional-grade valuation of Ensysce Biosciences.
- Customizable and Reusable: Tailored for flexibility, allowing repeated use for detailed forecasts on Ensysce.
Key Features
- Innovative Drug Development Platform: Leverages advanced technologies for developing pain management solutions.
- Robust Clinical Trial Management: Streamlined processes for efficient planning and execution of clinical trials.
- Customizable Research Models: Tailor research parameters to optimize drug efficacy and safety assessments.
- Integrated Financial Metrics: Evaluate key performance indicators to gauge financial health and growth potential for Ensysce Biosciences.
- Dynamic Reporting Tools: Visual presentations of research outcomes and financial data for informed decision-making.
How It Works
- 1. Access the Template: Download and open the Excel file containing Ensysce Biosciences, Inc. (ENSC) preloaded data.
- 2. Modify Assumptions: Adjust key inputs such as growth rates, WACC, and capital expenditures relevant to Ensysce.
- 3. View Results Instantly: The DCF model automatically computes the intrinsic value and NPV for Ensysce Biosciences.
- 4. Explore Scenarios: Evaluate various forecasts to assess different valuation possibilities for ENSC.
- 5. Present with Assurance: Deliver professional valuation insights to bolster your investment decisions regarding Ensysce Biosciences, Inc. (ENSC).
Why Choose Ensysce Biosciences, Inc. (ENSC)?
- Innovative Solutions: Cutting-edge technology designed to enhance drug delivery systems.
- Proven Expertise: Backed by a team of experienced professionals in the biotech field.
- Commitment to Safety: Focused on developing products that prioritize patient safety and efficacy.
- Robust Research: Extensive clinical trials support the reliability and effectiveness of our solutions.
- Industry Recognition: A trusted name in biosciences, known for quality and innovation.
Who Should Use This Product?
- Investors: Accurately assess Ensysce Biosciences, Inc.'s (ENSC) fair value prior to making investment choices.
- CFOs: Utilize a top-tier DCF model for financial analysis and reporting.
- Consultants: Seamlessly modify the template for client valuation reports.
- Entrepreneurs: Acquire insights into financial modeling practices of leading biotech firms.
- Educators: Employ it as a resource to illustrate valuation techniques in the classroom.
What the Template Contains
- Comprehensive DCF Model: Editable template with detailed valuation calculations tailored for Ensysce Biosciences, Inc. (ENSC).
- Real-World Data: Ensysce’s historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into the company's performance.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Charts and tables designed for clear, actionable results specific to Ensysce Biosciences, Inc. (ENSC).